Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayesian guidance released

This article was originally published in The Gray Sheet

Executive Summary

FDA says its Feb. 5 guidance on applying Bayesian statistics in medical device trials will help streamline device pivotal studies. The document finalizes a 2006 draft version and includes updates based on several years of input from industry and others. CDRH has been accepting pre-market submissions including Bayesian statistics since the late 1990s, but it has ramped up staff with expertise in the techniques since releasing the 2006 draft (1"The Gray Sheet" July 31, 2006). By allowing sponsors to incorporate data from prior studies, Bayesian statistics makes it possible to yield sufficient trial results from smaller or shorter trials (2"The Gray Sheet" May 31, 2004)
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel